The munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of only 16 of the 100 marijuana and psychedelic drug stocks that trade on North American stock exchanges and have market capitalizations in excess of $35M. Five (5) of them are in the Pure-Play Marijuana Drug Stocks Index sub-category and 11 are in the Pure-Play Psychedelic Compounds-Based Drug Stocks Index. 

40 of the 100 clinical-stage drug companies research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know) while the other 60 (see here) research the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them).

The Pure-Play Marijuana Drug Stocks Index

The constituents in both our Pure-Play Marijuana Drug Stocks Index and our Pure-Play Psychedelic Compounds-Based Drug Stocks Index have hyperlinks to 3 areas of additional information which are imperative for any individual considering investing in this sector:

• The company name is hyperlinked to its website to provide you with a description of the company and an analysis of its stock.
• The trading symbol is hyperlinked to additional financial data and commentary on the company (where available).
• The percentage increase YTD is hyperlinked to a chart of the company's stock performance YTD.

The "financial distress" percentage is sourced from macroaxis.com.

The 5 marijuana-based clinical-stage stocks are DOWN -0.2% so far in January and their performances are presented below in descending order:

1. Allied Corp. (ALID): UP +19.2%
   • engaged in the research, development, and production of cannabinoid health solutions in the United States and has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder
   • has about a 24% chance of experiencing some form of financial distress in the next two years of operation
2. Tetra Bio (TBPMF): UP +11.1%
   • engages in the discovery and development of immunomodulator drugs including PPP003 for painful dry eye and uveitis pain and HCC011 for hepatocellular carcinoma
   • has about a 28% chance of experiencing financial distress in the next 2 years of operation
3. Zynerba (ZYNE): DOWN -8.7%
   • operates as a clinical stage specialty pharmaceutical company
   • has more than a 55% chance of experiencing financial distress in the next 2 years of operation
4. Revive (RVVTF): DOWN -11.1%
   • focuses on the research and development of therapeutics for rare disorders and infectious diseases
   • has a very small chance of experiencing financial distress in the next few years
5. Corbus (CRBP): DOWN -12.9%
   • focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer
   • has a greater than 89% chance of experiencing financial distress in the next few years of operation

The Pure-Play Psychedelic Compounds-Based Drug Stocks Index

The 11 psychedelic compound-based clinical-stage stocks are divided into 2 groups based on their market capitalizations: $40M>$499.9M (Group 1) and $500M+ (Group 2). The Group 2 stocks are not included in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index because of their large market capitalizations but are detailed below to give the reader a broader picture of this market segment.

The 7 constituents in Group 1 have gone DOWN -8.4% so far in January and their performances are presented below in descending order:

1. Numinus (NUMIF): UP +33.3%
   • provides clients with testing of controlled compounds such as LSD, ketamine, DMT, MDMA, mescaline, psilocybin and psilocin as well as conducting research of both MDMA and psilocybin to treat PTSD, depression, anxiety, and addiction.
   • has over a 77% chance of experiencing financial distress in the next few years of operation
2. Red Light (TRUFF) UP +9.1%
   • plans to produce, market, and distribute a premium health and wellness brand of psilocybin truffles within the Netherlands.
   • has less about a 25% chance of experiencing financial distress in the next few years of operation.
3. Awakn (AWKNF): UP +3.4%
   • engaged in researching and developing psychedelic drugs focuses to treat addiction as well as delivering psychedelic treatments for addiction in clinics in the UK and EU.
   • has a 50% chance of experiencing financial distress in the next 2 years of operation.
   • Read: Awakn Life Sciences: Wake Up To The Huge Potential
4. Cybin (CYBN): DOWN -12.5%
   • focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
   • has over a 62% chance of experiencing financial distress in the next few years of operation.
5. Seelos (SEEL): DOWN -13.5%
   • focused on developing products that address significant unmet needs in the Central Nervous System disorders and other rare disorders.
   • has over a 74% chance of experiencing financial distress in the next few years of operation.
6. Field Trip (FTRP): DOWN -18.7%
   • focused on building centers for psychedelic therapies across North America and Europe.
   • has about a 27% chance of experiencing some form of financial distress in the next two years of operation.
7. Small Pharma (DMTTF): DOWN -28.0% 
   • focused on developing N,N-dimethyltryptamine and a pipeline of novel patent-protected deuterium-enriched tryptamine compounds in combination with psychotherapy as potential rapid onset, sustained treatments for depression and other mental health disorders.
   • has over a 77% chance of experiencing some form of financial distress in the next two years of operation

The 4 constituents with market caps above $500M (Group 2) have gone DOWN -18.9% so far in January. Their performances are presented below in descending order:

1. GH Resources (GHRS): DOWN -17.7%
   • about 58% chance of experiencing financial distress in the next two years of operation.
2. Mind Medicine (MNMD): DOWN -18.8%
   • above 62% chance of experiencing financial distress in the next few years of operation.
3. Compass Pathways (CMPS): DOWN -19.0%
   • about 58% chance of experiencing financial distress in the next few years of operation.
4. Atai (ATAI): DOWN -21.9%
   • above 56% chance of experiencing financial distress in the next few years of operation.

In summary, the  munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index has gone DOWN -5.0% month-to-date and is now DOWN -66.2% from its 52-week high.